Scholarlink

Introduction <p>A phase&#xa0;4, prospective, open-label study of low-sodium oxybate (LXB) in narcolepsy (type&#xa0;1 [NT1] or 2 [NT2]) or idiopathic hypersomnia included novel symptom outcomes important to patients (Jazz DUET; NCT05875974; registered 16 May&#xa0;2023). Primary results from the narcolepsy cohort, including LXB effectiveness (nighttime sleep/daytime symptoms/overall disease severity) and safety are reported here.</p> Methods <p>DUET included screening, 8-day baseline (BL; off-LXB), 2–8-week LXB dose titration/optimization, 2-week stable-dose, 8-day end-of-treatment (EOT; on-LXB), and safety follow-up periods. At BL and EOT, participants underwent nocturnal polysomnography (PSG) and completed Epworth Sleepiness Scale (ESS; primary endpoint), Narcolepsy Severity Scale (NSS [NT1]; NSS-2 [NT2]), and Patient Global Impression of Severity (PGI-S) and Change (PGI-C); eDiaries for sleep quality and cataplexy (NT1 only) were completed daily for 8&#xa0;days before PSGs. Least-squares mean (LSM) changes were adjusted for BL values.</p> Results <p>Thirty-four participants completed the study and were analyzed (NT1, <i>n</i> = 16; NT2, <i>n</i> = 18); LSM (SE) change in ESS score (BL to EOT), − 7.7 (0.9), <i>P</i> &lt; 0.0001. At EOT versus BL, transitions to lighter stages of sleep decreased (LSM [SE] − 13.1 [2.9], <i>P</i> &lt; 0.0001), N3 duration increased (45.0 [8.8] min, <i>P</i> &lt; 0.0001), and nocturnal awakenings decreased (− 3.2 [0.9], <i>P</i> = 0.0013). LSM [SE] changes in NSS and NSS-2 scores were − 19.7 (2.7) and − 11.3 (1.6). Most participants reported improved sleep quality and overall narcolepsy disease and fewer cataplexy attacks. Treatment-emergent adverse events were consistent with the known LXB safety profile.</p> Conclusion <p>DUET study results demonstrated novel nighttime sleep/daytime symptom improvements in participants with narcolepsy treated with open-label LXB.</p> Trial Registration <p>ClinicalTrials.gov identifier, NCT05875974.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Logan D. Schneider,
  • Chad M. Ruoff,
  • David T. Plante,
  • Deborah A. Nichols,
  • Teresa L. Steininger,
  • Douglas S. Fuller,
  • M. Todd Kirby,
  • Sarah Akerman,
  • Jessica K. Alexander,
  • Marisa Whalen,
  • Alyssa Cairns

摘要

Introduction

A phase 4, prospective, open-label study of low-sodium oxybate (LXB) in narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia included novel symptom outcomes important to patients (Jazz DUET; NCT05875974; registered 16 May 2023). Primary results from the narcolepsy cohort, including LXB effectiveness (nighttime sleep/daytime symptoms/overall disease severity) and safety are reported here.

Methods

DUET included screening, 8-day baseline (BL; off-LXB), 2–8-week LXB dose titration/optimization, 2-week stable-dose, 8-day end-of-treatment (EOT; on-LXB), and safety follow-up periods. At BL and EOT, participants underwent nocturnal polysomnography (PSG) and completed Epworth Sleepiness Scale (ESS; primary endpoint), Narcolepsy Severity Scale (NSS [NT1]; NSS-2 [NT2]), and Patient Global Impression of Severity (PGI-S) and Change (PGI-C); eDiaries for sleep quality and cataplexy (NT1 only) were completed daily for 8 days before PSGs. Least-squares mean (LSM) changes were adjusted for BL values.

Results

Thirty-four participants completed the study and were analyzed (NT1, n = 16; NT2, n = 18); LSM (SE) change in ESS score (BL to EOT), − 7.7 (0.9), P < 0.0001. At EOT versus BL, transitions to lighter stages of sleep decreased (LSM [SE] − 13.1 [2.9], P < 0.0001), N3 duration increased (45.0 [8.8] min, P < 0.0001), and nocturnal awakenings decreased (− 3.2 [0.9], P = 0.0013). LSM [SE] changes in NSS and NSS-2 scores were − 19.7 (2.7) and − 11.3 (1.6). Most participants reported improved sleep quality and overall narcolepsy disease and fewer cataplexy attacks. Treatment-emergent adverse events were consistent with the known LXB safety profile.

Conclusion

DUET study results demonstrated novel nighttime sleep/daytime symptom improvements in participants with narcolepsy treated with open-label LXB.

Trial Registration

ClinicalTrials.gov identifier, NCT05875974.